Webinar: BioAssay Express Demonstration & CDD Vault ELN for Assay Registration: June 28, 2019
Practical Demonstration of BioAssay Express (BAE) and CDD Vault ELN for Assay Registration
Friday, June 28, 2019 • 9:00 AM PT • 12:00 PM ET • 16:00 GMT
In our recent "Better Science Through Metadata" webinar, our expert panel of scientists (Dr. Ellen Berg and Dr. Isabella Feierberg) discussed the importance of metadata and their vision for how assay annotation will shape the future of drug discovery.
During this webinar, the panelists also discussed how CDD's BioAssay Express (BAE) provides a smart tool that incorporates a hybrid machine-learning approach with expertly curated ontologies to unambiguously and easily annotate your assay metadata. BAE also provides a powerful engine for searching, comparing, and analyzing your assays so much so that parts of BAE, namely Assay Annotations, have also been implemented into CDD Vault ELN for Assay Registration.
We had such a great response to this webinar that we are now scheduling a practical live webinar on June 28th to demonstrate the use of BAE and the CDD Vault ELN.
Please join Dr. Samantha Jeschonek, Research Scientist at Collaborative Drug Discovery, as she walks us through typical use-case scenarios for users of BAE and the CDD Vault ELN.
Featuring These Leading Scientists...
Ellen L. Berg
Chief Scientific Officer, Translational Biology for Eurofins Discovery
Ellen L. Berg, PhD is an entrepreneur and scientific leader in drug discovery technology innovation.
She is Chief Scientific Officer, Translational Biology for Eurofins Discovery and a principal at Alto Predict LLC. Dr.
Berg was the lead inventor of the BioMAP® platform of human primary cell-based disease models, now successfully commercialized by Eurofins and serving the pharmaceutical and consumer products industries to deliver safer and more effective products.
In previous positions, Dr. Berg was co-founder and CSO of BioSeek, Inc. and led a research team at Protein Design Labs, Inc.
She received her PhD from Northwestern University and was a postdoctoral fellow at Stanford University, where she was a fellow of the American Cancer Society and a Special Fellow of the Leukemia Society of America.
She is currently focused on working with industry, academic, and government stakeholders to incorporate non-animal, human-based in vitro and in silico predictive models into the drug discovery process and helping to promote the adoption of these platforms by regulatory agencies.
Dr. Berg holds several patents in the field of inflammation, and has authored over 80 publications.
Associate Principal Scientist
Isabella Feierberg, PhD has over 15 years of experience as a computational chemist in drug discovery.
After her PhD in computational studies of biomolecular structure-function relationships at Uppsala University in Sweden, she joined AstraZeneca where she supports the early drug discovery pipeline.
Her research ranges from individual drug discovery projects to method development for High Throughput Screening analysis, assay informatics, precompetitive collaborations and FAIR data.
Being an end user of experimental data for analysis, modelling and decision making, she relies heavily on high quality data and metadata.
Dr. Feierberg is currently involved with the Pistoia Alliance to plan a pre-competitive collaboration on high quality curation and FAIRification of public domain assay protocols with public ontologies.